Table 3 Clinical and molecular features of the patients enrolled in the study
| Â | N | Frequency | |
|---|---|---|---|
Molecular Subtype | Luminal A | 23 | 28.40% |
Luminal B | 20 | 24.69% | |
HER2+ | 20 | 24.69 | |
Triple Negative | 18 | 22.22 | |
Grading | G1 | 14 | 17.50% |
G2 | 16 | 20.00% | |
G3 | 50 | 62.50% | |
TNM stage | I | 52 | 64.20% |
II | 18 | 22.22% | |
III | 10 | 12.35% | |
IV | 1 | 1.23% | |
Metastases | No | 71 | 87.65% |
Yes | 10 | 12.35% | |
Relapse | No | 76 | 93.83% |
Yes | 5 | 6.17% | |
ER | Negative | 36 | 44.44% |
Positive | 45 | 55.56% | |
PgR | Negative | 40 | 49.38% |
Positive | 41 | 50.62% | |
HER2 | Negative | 28 | 34.57% |
Score 1 | 9 | 11.11% | |
Score 2 | 15 | 18.52% | |
Score 3 | 29 | 35.80 | |
Ki67 | ≤ 20% | 20 | 24.69 |
> 20% | 61 | 75.31 | |